The Chamber continues to work with other business groups and
government officials to ensure that the state's health care
reform law is implemented as it was intended. Various
aspects of Chapter 58 are currently being reviewed,
including finance mechanisms and minimum creditable coverage
standards for the individual mandate.
The Chamber joined several business organizations earlier
this week in signing a letter urging House members to
support a budget amendment (Amendment 472) that removes
prescription drug coverage from the Minimum Creditable
Coverage standard for plans under the new health care law.
Currently, thousands of citizens have plans without drug
coverage, but, under the law, they will be required to
purchase new, more costly plans next year that contain this
coverage or face penalties. Amendment 472 will ensure that
these individuals, along with employers, have options in
choosing their plans, while helping to avoid paying more for
health care.
As these
discussions continue, the Chamber will continue to advocate
on behalf of members, and ensure that employers are not
unfairly burdened.
The second phase of health care reform is also underway, as
the House is now working on their version of legislation
dealing with cost. Earlier this month, the Senate
passed health care cost-containment legislation that had
been proposed by Senate President Therese Murray at the
beginning of the year.
The Chamber supports several provisions of the bill,
including statewide adoption of computerized physician order
entry systems, statewide adoption and compatibility of
electronic medical records, and loan forgiveness and
workforce housing assistance programs for nurses and primary
care physicians. These proposals have the potential to
reduce medical errors, drive down overall health care costs,
meet the needs of the high-growth health care industry, and
attract and retain talented medical professionals.
However, the legislation also includes a “gift ban”
provision that would inhibit product marketing and
information-sharing by the life sciences industry. The
Chamber believes that Massachusetts should promote, rather
than inhibit, the ability of life science companies to
educate and inform health care providers, and effectively
and ethically market their products. The Chamber continues
to voice serious concerns to legislative leaders about the
impacts – both intended and unintended – that this provision
would have on the state’s world-renowned life sciences
cluster and its ability to realize its full potential in the
state.